Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Neovasc shares soar after medical journal publishes positive study data on its heart treatment

Proactive Investors Thursday, 23 May 2019
Neovasc Inc (TSE:NVCN) (NASDAQ:NVCN) saw its shares soar on Thursday after the International Journal of Cardiology published a peer-reviewed article confirming the long-term safety of the company’s angina therapy. Based in Vancouver, the medical device company is developing the Reducer for the treatment of refractory angina, a debilitating heart condition that affects nearly 1.8 million people in the US alone. Shares of Neovasc gained more than 47%, or C$0.30, to reach C$0.93 in Toronto before settling at C$0.63 by mid-Thursday, while it jumped nearly 43% in the US to sit at US$0.68. READ: Ventripoint Diagnostics to bring its cardiac-imaging technology to France In an article titled, “Safety and efficacy of Coronary Sinus Reducer implantation at 2-year follow-up,” the IJC highlighted a 50-patient study that found the Reducer remained safe in the longer-term outcome with no device-related adverse events. Additionally, patients with the device maintained a reduction of angina symptoms and reported an improved quality of life after a two-year follow-up. "This study shows us that the Reducer has a sustained therapeutic effect at two years across a large patient population,” said Professor Shmuel Banai, medical director of Neovasc. “In addition, we believe this study provides valuable long-term safety data that further supports cardiologists use of the Reducer as a therapeutic option for patients suffering from refractory angina. This data supports our belief that the Reducer offers refractory angina patients a safe and effective treatment option, filling a void in a market where there are currently limited therapeutic options." Neovasc develops, manufactures and markets cardiovascular products including the Reducer, which is not currently commercially available in the United States. Also in its arsenal is the Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. Contact Angela at [email protected] Follow her on Twitter @AHarmantas
0
shares
ShareTweetSavePostSend
 
Credit: CBS 4 Denver - Published < > Embed
News video: Study: CBD Effective In Treating Heroin Addiction

Study: CBD Effective In Treating Heroin Addiction 00:41

Cannabidiol, the non-psychoactive ingredient in hemp and marijuana, could treat opioid addiction, a new study says. Curtis Silva reports.

You Might Like


Recent related videos from verified sources

Cancer Patients Who Received Radiation Therapy Find Heart Help With Statins [Video]Cancer Patients Who Received Radiation Therapy Find Heart Help With Statins

Radiation therapy has brought new life to millions of cancer survivors. But according to UPI, a new study says that treatment comes with great risk. That's because over half of all cancer patients..

Credit: Wochit News     Duration: 00:38Published

Suicide Rate Among US Young People Continues to Rise [Video]Suicide Rate Among US Young People Continues to Rise

Suicide Rate Among US Young People Continues to Rise New research conducted by associates of Harvard Medical School and published in the medical journal JAMA, found the rate of deaths by suicide..

Credit: Wibbitz Top Stories     Duration: 01:02Published

Your Facebook Profile Can Reveal Your Medical Conditions [Video]Your Facebook Profile Can Reveal Your Medical Conditions

Your Facebook Profile Can Reveal Your Medical Conditions Your Facebook profile could be giving away too much personal information. A study published in peer-reviewed journal PLOS One has revealed that..

Credit: Wibbitz Top Stories     Duration: 01:16Published

Dogs Can Detect Lung Cancer With 97% Accuracy [Video]Dogs Can Detect Lung Cancer With 97% Accuracy

Dogs Can Detect Lung Cancer With 97% Accuracy In a new study, researchers used three beagles to sniff out different blood samples. The report can be found in 'The Journal of the..

Credit: Wibbitz Top Stories     Duration: 01:27Published


Recent related news from verified sources

Orthocell completes CelGro study accelerating dental implant treatments

Orthocell Ltd (ASX:OCC) has completed the CelGro® single-stage dental implant study designed to assess effectiveness and predictability in accelerating...
Proactive Investors

ContraVir Pharmaceuticals stock soars after its Hepatitis B drug appears in medical journal article

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) shares popped after an article highlighting the success of its Hepatitis B treatment was published in a medical...
Proactive Investors

Investors cheer ContraVir's positive results from a human-liver experiment using its CRV431 drug candidate

Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) increased by double-digits Monday after reporting positive results from a human-liver experiment using its...
Proactive Investors

Ra Medical Clinical Study Aims to Show DABRA Keeps Arteries Healthy Longer

Ra Medical Clinical Study Aims to Show DABRA Keeps Arteries Healthy Longer
CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED) is conducting a study to demonstrate the DABRA Excimer Laser System delivers effective,...
Business Wire


Other recent news in Business

Weight of bags taken out of circulation in AUSTRALIA equivalent to more than 780 elephants'He has a point': Christine Lagarde tackled Trump's trade war, CLIMATE CHANGE, and the gender pay gap on the Daily Show with Trevor Noah
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.